Utah is currently home to 1204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
NCT04676802
Recruiting
In the US, pain management after surgery for surgical treatment of osteoarthritis at the base of the thumb typically consists of prescription opioids during the early recovery phase. Given the highly addictive nature of prescription opioids, guidelines are being evaluated by hand surgeons to reduce opioid use while still maintaining pain control after surgery. A promising approach is to use non-narcotic medication as the first line of treatment. The purpose of this study is to demonstrate the ef... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
08/02/2025
Locations: University of Utah Health Care, Salt Lake City, Utah
Conditions: Pain, Postoperative, Osteoarthritis Thumb
Register for Updates
A Study of LY4088044 in Healthy Participants
NCT07090785
Recruiting
The purpose of this study is to evaluate how well LY4088044 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4088044 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 92 weeks for Parts A, B, and C, excluding screening.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/01/2025
Locations: ICON, Salt Lake City, Utah
Conditions: Healthy
Register for Updates
A Study to Investigate Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis
NCT07001800
Recruiting
The purpose of this study is to evaluate if ataciguat slows the progression of moderate calcific aortic valve stenosis in adults.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/01/2025
Locations: University of Utah Hospital & Clinics, Salt Lake City, Utah
Conditions: Moderate Aortic Valve Stenosis
Register for Updates
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079
Recruiting
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
Register for Updates
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742
Recruiting
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/01/2025
Locations: Retina Associates of Utah, Salt Lake City, Utah
Conditions: Wet Age Related Macular Degeneration, wAMD
Register for Updates
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670
Recruiting
The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers. This study is open to adults with ulcerative PG with at least 1 ulcer that measures between 5 cm\^2 to 80 cm\^2 in size. This study has 2 parts. In Part 1, participants are put into groups randomly, which means by chance. 1 group gets spesolimab and the other group gets placebo. Placebo injections look... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: University of Utah Health, Murray, Utah
Conditions: Pyoderma Gangrenosum
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in pediatric participants with moderate to severe AD who are candidates for systemic therapy. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
08/01/2025
Locations: Jordan Valley Dermatology & Research Center /ID# 267092, South Jordan, Utah
Conditions: Atopic Dermatitis
Register for Updates
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
NCT06365060
Recruiting
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/01/2025
Locations: University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah
Conditions: Smoldering Multiple Myeloma
Register for Updates
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137
Recruiting
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Huntsman Cancer Institute ( Site 0042), Salt Lake City, Utah
Conditions: Non Small Cell Lung Cancer
Register for Updates
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
NCT06098079
Recruiting
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Velocity Clinical Research, Salt Lake City, West Jordan, Utah
Conditions: Obesity
Register for Updates
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
NCT06094010
Recruiting
This study consists of two parts: Part A Surveillance and Part B Transmission. The main purpose of Part A is to evaluate the prevalence of pre-dose and treatment-emergent amino acid substitutions in pediatric participants' susceptibility \<12 years with influenza treated with baloxavir marboxil. Part B will include a subset of Part A participants who have household contacts (HHCs) recruited to the study. Part B will evaluate the incidence of onward influenza transmission from pediatric index p... Read More
Gender:
ALL
Ages:
Between 3 weeks and 11 years
Trial Updated:
08/01/2025
Locations: Velocity Clinical Research, Salt Lake City, West Jordan, Utah
Conditions: Influenza
Register for Updates
First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
NCT06043817
Recruiting
Study STX-721-101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR/HER2 exon 20 insertion (ex20ins) mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: University of Utah - Huntsman Cancer Institute - PPDS, Salt Lake City, Utah
Conditions: Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
Register for Updates